Valuation: VolitionRx Limited

Market Cap 8.33M 7.32M 6.8M 6.24M 11.73M 802M 11.91M 80.8M 31.57M 394M 31.27M 30.6M 1.36B P/E 2026 *
-0.45x
P/E 2027 * -0.72x
Enterprise Value 8.33M 7.32M 6.8M 6.24M 11.73M 802M 11.91M 80.8M 31.57M 394M 31.27M 30.6M 1.36B EV / Sales 2026 *
3.36x
EV / Sales 2027 * 1.45x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day-7.41%
1 week-9.09%
Current month-25.93%
1 month-18.70%
3 months-64.31%
6 months-82.27%
Current year-80.44%
1 week 0.99
Extreme 0.99
1.19
1 month 0.99
Extreme 0.99
1.53
Current year 0.99
Extreme 0.99
7.73
1 year 0.99
Extreme 0.99
16
3 years 0.99
Extreme 0.99
28
5 years 0.99
Extreme 0.99
82.8
10 years 0.99
Extreme 0.99
136.8
Manager TitleAgeSince
Chief Executive Officer 55 2011-10-05
Director of Finance/CFO 56 2021-01-31
Chief Tech/Sci/R&D Officer 49 2024-03-31
Director TitleAgeSince
Director/Board Member 55 2011-10-05
Director/Board Member 77 2011-10-05
Director/Board Member 64 2019-10-08
Date Insider Type Main position Quantity % Market Cap.
3/17/26
Concord International, Inc.
OtherCompany 0 0%
3/17/26 Tax

Company Secretary

3,948 0.0029%
3/17/26 Tax

Chief Technology Officer

5,310 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-7.41%-9.09%-93.15%-96.15% 8.33M
+0.95%-.--%+115.11%+11.80% 20.03B
-2.19%-4.26%+139.97%+105.56% 4.52B
-0.18%-2.84%+108.91%+185.51% 3.56B
-2.73%-0.20%+51.67%-32.29% 2.23B
-0.90%+1.56%-30.96%-37.12% 2.07B
-1.25%-6.52%+189.25%+256.77% 1.92B
-4.11%-6.63%+149.45%-45.83% 997M
-0.54%-4.03%-7.28%+32.69% 855M
-3.59%-6.57%-43.37%-17.58% 479M
Average -2.19%-3.17%+57.96%+36.33% 3.67B
Weighted average by Cap. -0.22%-1.33%+105.31%+46.13%

Financials

2026 *2027 *
Net sales 2.48M 2.18M 2.02M 1.86M 3.49M 239M 3.54M 24.03M 9.39M 117M 9.3M 9.1M 406M 5.73M 5.04M 4.68M 4.3M 8.07M 552M 8.2M 55.61M 21.73M 271M 21.52M 21.06M 939M
Net income -22.2M -19.5M -18.14M -16.64M -31.27M -2.14B -31.75M -215M -84.14M -1.05B -83.35M -81.55M -3.63B -19.62M -17.23M -16.02M -14.7M -27.63M -1.89B -28.06M -190M -74.34M -929M -73.65M -72.06M -3.21B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
26-07-24 US$1.000 -7.41% 176,835
26-07-23 US$1.080 +3.85% 213,442
26-07-22 US$1.040 -6.31% 430,233
26-07-21 US$1.110 -1.77% 295,724
26-07-20 US$1.130 +2.73% 221,905
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.000USD
Average target price
16.97USD
Spread / Average Target
+1,596.60%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock